Open Access
Open access
volume 20 issue 1 pages 24-33

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study

Bruce Rashbaum 1
CD Spinner 2
Cheryl McDonald 3
Cristina Mussini 4
John Jezorwski 5
Donghan Luo 6
Erika Van Landuyt 7
Kimberley Brown 6
Eric Y Wong 8
1
 
Capital Medical Associates, Washington, DC, USA;
3
 
Tarrant County Infectious Disease Associates, Fort Worth, TX, USA;
5
 
Janssen Research & Development, LLC, Pennington, NJ, USA;
6
 
Janssen Research & Development, LLC, Titusville, NJ, USA;
7
 
Janssen Research & Development, Beerse, Belgium;
8
 
Janssen Scientific Affairs, LLC, Titusville, NJ, USA
Publication typeJournal Article
Publication date2019-01-02
scimago Q2
wos Q3
SJR0.693
CiteScore2.6
Impact factor1.8
ISSN25787489, 25787470
Infectious Diseases
Pharmacology (medical)
Found 
Found 

Top-30

Journals

1
HIV Research and Clinical Practice
1 publication, 20%
Future Virology
1 publication, 20%
Frontiers in Pharmacology
1 publication, 20%
Frontiers in Medicine
1 publication, 20%
BMJ Open
1 publication, 20%
1

Publishers

1
2
Frontiers Media S.A.
2 publications, 40%
Taylor & Francis
1 publication, 20%
1 publication, 20%
BMJ
1 publication, 20%
1
2
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
5
Share
Cite this
GOST |
Cite this
GOST Copy
Rashbaum B. et al. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study // HIV Research and Clinical Practice. 2019. Vol. 20. No. 1. pp. 24-33.
GOST all authors (up to 50) Copy
Rashbaum B., Spinner C., McDonald C., Mussini C., Jezorwski J., Luo D., Van Landuyt E., Brown K., Wong E. Y. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study // HIV Research and Clinical Practice. 2019. Vol. 20. No. 1. pp. 24-33.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1080/15284336.2019.1608714
UR - https://doi.org/10.1080/15284336.2019.1608714
TI - Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study
T2 - HIV Research and Clinical Practice
AU - Rashbaum, Bruce
AU - Spinner, CD
AU - McDonald, Cheryl
AU - Mussini, Cristina
AU - Jezorwski, John
AU - Luo, Donghan
AU - Van Landuyt, Erika
AU - Brown, Kimberley
AU - Wong, Eric Y
PY - 2019
DA - 2019/01/02
PB - Taylor & Francis
SP - 24-33
IS - 1
VL - 20
PMID - 31303147
SN - 2578-7489
SN - 2578-7470
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2019_Rashbaum,
author = {Bruce Rashbaum and CD Spinner and Cheryl McDonald and Cristina Mussini and John Jezorwski and Donghan Luo and Erika Van Landuyt and Kimberley Brown and Eric Y Wong},
title = {Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study},
journal = {HIV Research and Clinical Practice},
year = {2019},
volume = {20},
publisher = {Taylor & Francis},
month = {jan},
url = {https://doi.org/10.1080/15284336.2019.1608714},
number = {1},
pages = {24--33},
doi = {10.1080/15284336.2019.1608714}
}
MLA
Cite this
MLA Copy
Rashbaum, Bruce, et al. “Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.” HIV Research and Clinical Practice, vol. 20, no. 1, Jan. 2019, pp. 24-33. https://doi.org/10.1080/15284336.2019.1608714.